Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MABp1 for moderate to severe hidradenitis suppurativa
2015-002321-20Phase 2Completed
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing MABp1 with Placebo (2 arms). Primary endpoint: HiSCR response at week 12. Started Jun 2015; status: completed.
02
Drugs
bermekimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2015-002321-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002321-20.